Results 211 to 220 of about 516,619 (288)

Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. [PDF]

Front Immunol
Yang S, Chuan Z, Yang S, Nie J.
europepmc   +1 more source

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. [PDF]

J Hematol Oncol
Lou J, Lyu Y.
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions. [PDF]

Cancers (Basel)
Ciammella P, Bavieri A, Nizzoli ME, Alì E.   +3 more
europepmc   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, Volume 115, Issue 11, Page 2603-2615, November 2026.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

Angewandte Chemie, Volume 138, Issue 42, 12 October 2026.
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco, Fabio Baroni, Angela Capolupo, Sofia Petrocchi, Jonathan Zöller, Linda Cerofolini, Pasquale Russomanno, Rebecca Calamandrei, Bianca Susini, Siyu Lin, Fabio D'Amici, Enrico Ravera, Julian Langer, Marco Fragai   +13 more
wiley   +2 more sources

Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis. [PDF]

Front Immunol
Yan Y, Gao W, Zhu Z, Zheng L, Lu Y, Sun L, Jiang G.   +6 more
europepmc   +1 more source

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

European Journal of Haematology, Volume 117, Issue 5, Page 1181-1197, November 2026.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies. [PDF]

Front Immunol
Zhai X, Rong Z, Fu L, Gu Y, Dong B, Yao D, Pang X, Cui Y.   +7 more
europepmc   +1 more source

Bioorthogonal Chemistry in Neurobiology: From Imaging to Proteomics

ChemBioChem, Volume 27, Issue 20, 28 October 2026.
This review highlights emerging strategies for labeling neuronal proteins, enabling visualization and quantitative analysis of their expression, localization, and dynamics. By combining genetic code expansion (GCE), metabolic labeling, and click chemistry‐based labeling, these approaches provide powerful routes to study proteins in specific cells and ...
Neil Taylor, João de Sousa‐Lourenço, Ivana Nikić‐Spiegel   +2 more
wiley   +1 more source